<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002024</url>
  </required_header>
  <id_info>
    <org_study_id>029B</org_study_id>
    <secondary_id>ICM 1257A</secondary_id>
    <nct_id>NCT00002024</nct_id>
  </id_info>
  <brief_title>Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections</brief_title>
  <official_title>Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To provide ganciclovir on a compassionate use basis to immunocompromised patients with&#xD;
      serious cytomegalovirus (CMV) infections and to study safety and efficacy in this patient&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cytomegalovirus Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Topical acyclovir.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Mild to moderate cytomegalovirus (CMV) infections that fail to satisfy the clinical&#xD;
             severity criteria.&#xD;
&#xD;
          -  Transplant where a trial reduction of immunosuppressive drug treatment is not&#xD;
             feasible.&#xD;
&#xD;
          -  Congenital or neonatal CMV infections where there is not documented congenital or&#xD;
             acquired immunodeficiency.&#xD;
&#xD;
          -  Neutropenia unless it is pre-existing.&#xD;
&#xD;
          -  Thrombocytopenia unless it is pre-existing.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other myelosuppressive drugs such as cancer chemotherapy agents, interferon,&#xD;
             foscarnet, or nucleoside analogs.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Mild to moderate cytomegalovirus (CMV) infections that fail to satisfy the clinical&#xD;
             severity criteria.&#xD;
&#xD;
          -  Transplant where a trial reduction of immunosuppressive drug treatment is not&#xD;
             feasible.&#xD;
&#xD;
          -  Congenital or neonatal CMV infections where there is not documented congenital or&#xD;
             acquired immunodeficiency.&#xD;
&#xD;
          -  Neutropenia unless it is pre-existing.&#xD;
&#xD;
          -  Thrombocytopenia unless it is pre-existing.&#xD;
&#xD;
        Patients must be immunocompromised with a serious cytomegalovirus (CMV) infection. This&#xD;
        would include pneumonia, gastrointestinal disease, hepatitis, or other organ-specific&#xD;
        disease or severe wasting syndrome. Patients with pre-existing neutropenia or&#xD;
        thrombocytopenia, and immediate life-threatening disease can be included if the&#xD;
        investigator believes that delay in starting ganciclovir therapy is not advisable. In such&#xD;
        patients, the investigator must advise the patient of the risk of further marrow&#xD;
        suppression and the increased risk of infection or bleeding; and the patient must sign an&#xD;
        amended informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Roche Global Development - Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien M. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1996 Jun 6;334(23):1491-7. doi: 10.1056/NEJM199606063342302.</citation>
    <PMID>8618603</PMID>
  </reference>
  <verification_date>September 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Immune Tolerance</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Drugs, Investigational</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

